B. Batley

发表

Exploring the binding preferences/specificity in the active site of human cathepsin E

T. Blundell, B. Dunn, J. Kay, 1995, Proteins.

Heat stress increases cardiac HSP72i but fails to reduce myocardial infarct size in rabbits 24 hours later

K. Gallagher, B. Batley, L. Saganek, 1997, Basic Research in Cardiology.

Topographically designed peptidomimetic inhibitors of human renin: Incorporation of novel, tethered P1 → P3 side chain functionalization

C. Humblet, E. Lunney, J. M. Hamby, 1994 .

Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor.

W. Denny, H. D. Showalter, S. Trumpp-Kallmeyer, 1999, Journal of medicinal chemistry.

Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitors.

A. Doherty, M. J. Ryan, M. Taylor, 1992, Journal of medicinal chemistry.

Disparity between blood pressure and PRA inhibition after administration of a renin inhibitor to anesthetized dogs: methodological considerations.

R. K. Palmer, D. Taylor, M. Ryan, 1993, Clinical and experimental hypertension.

TETRAHYDROISOQUINOLINE AS A PHENYLALANINE REPLACEMENT IN RENIN INHIBITORS

E. Lunney, H. W. Hamilton, B. Steinbaugh, 1994 .

Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→ P3)-P1' sites

J. M. Hamby, M. Plummer, G. Hingorani, 1993 .

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

A. Doherty, H. D. Showalter, J. M. Hamby, 2001, Journal of medicinal chemistry.

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

A. Doherty, J. M. Hamby, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.

J. M. Hamby, A. Kraker, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation.

C. Humblet, E. Lunney, B. Dunn, 1993, Journal of medicinal chemistry.

In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.

R. Panek, G. Lu, C. Connolly, 1998, The Journal of pharmacology and experimental therapeutics.

Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor.

A. Doherty, R. Panek, G. Lu, 1997, Life sciences.

Synthesis and structure-activity relationships of 7-substituted 3-(2,6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60c-src

W. Denny, G. Rewcastle, H. D. Showalter, 2000 .

Effect of an orally active renin inhibitor Cl-992 on blood pressure in normotensive and hypertensive monkeys.

J. Keiser, D. Taylor, M. Ryan, 1994, The Journal of pharmacology and experimental therapeutics.